Unit of Epidemiology, Institute of Environmental Medicine, Karolinska Institutet, Stockholm, Sweden; Department of Respiratory Medicine and Allergy, Theme Inflammation and Ageing, Karolinska University Hospital, Stockholm, Sweden.
Division of Respiratory Medicine, Department of Medicine Solna, Karolinska Institutet, Stockholm, Sweden; Department of Respiratory Medicine and Allergy, Theme Inflammation and Ageing, Karolinska University Hospital, Stockholm, Sweden.
Chest. 2024 Nov;166(5):1082-1092. doi: 10.1016/j.chest.2024.05.014. Epub 2024 Jun 8.
An autoimmune component in the cause of sarcoidosis has long been debated, but population-based data on the clustering of immune-mediated diseases (IMDs) and sarcoidosis in individuals and families suggestive of shared cause are limited.
Do patients with a history of IMDs have a higher risk of sarcoidosis and do IMDs cluster in families with sarcoidosis?
We conducted a case-control-family study (2001-2020). Patients with sarcoidosis (N = 14,146) were identified in the Swedish National Patient Register using a previously validated definition (≥ 2 International Classification of Diseases [ICD]-coded inpatient or outpatient visits). At diagnosis, patients were matched to up to 10 control participants from the general population (N = 118,478) for birth year, sex, and residential location. Patients, control participants, and their first-degree relatives (FDRs; Multi-Generation Register) were ascertained for IMDs by means of ICD codes in the Patient Register (1968-2020). Conditional logistic regression was used to estimate ORs and 95% CIs of sarcoidosis associated with a history of IMDs in patients and control participants and in FDRs.
Patients with sarcoidosis exhibited a higher prevalence of IMDs compared with control participants (7.7% vs 4.7%), especially connective tissue diseases, cytopenia, and celiac disease. Familial aggregation was observed across IMDs; the strongest association was with celiac disease (OR, 2.09; 95% CI, 1.22-3.58), followed by cytopenia (OR, 1.88; 95% CI, 0.97-3.65), thyroiditis (OR, 1.72; 95% CI, 1.14-2.60), skin psoriasis (OR, 1.70; 95% CI, 1.34-2.15), inflammatory bowel disease (OR, 1.53; 95% CI, 1.14-2.03), immune-mediated arthritis (OR, 1.49; 95% CI, 1.20-1.85), and connective tissue disease (OR, 1.39; 95% CI, 1.00-1.93).
This study showed that IMDs confer a higher risk of sarcoidosis and they aggregate in families with sarcoidosis, signaling a shared cause between IMDs and sarcoidosis. Our findings warrant further evaluation of shared genetic mechanisms.
自身免疫成分在结节病发病机制中的作用一直存在争议,但人群中与个体和家族中结节病相关的免疫介导疾病(IMD)聚集相关的基础数据有限,提示可能存在共同病因。
有 IMD 病史的患者发生结节病的风险是否更高,IMD 是否会在有结节病的家族中聚集?
我们进行了病例对照家族研究(2001-2020 年)。使用先前验证的定义(≥ 2 次国际疾病分类 [ICD] 编码的住院或门诊就诊),在瑞典国家患者登记处确定结节病患者(N=14146)。在诊断时,患者按出生年份、性别和居住地点与来自一般人群的最多 10 名对照参与者(N=118478)相匹配。通过患者登记处的 ICD 代码(1968-2020 年)确定患者、对照参与者及其一级亲属(多代登记处)的 IMD。采用条件逻辑回归估计患者和对照参与者以及一级亲属中与 IMD 相关的结节病的比值比(OR)和 95%置信区间(CI)。
与对照参与者相比(7.7%比 4.7%),结节病患者的 IMD 患病率更高,尤其是结缔组织疾病、细胞减少症和乳糜泻。IMD 存在家族聚集现象;与乳糜泻的关联最强(OR,2.09;95%CI,1.22-3.58),其次是细胞减少症(OR,1.88;95%CI,0.97-3.65)、甲状腺炎(OR,1.72;95%CI,1.14-2.60)、皮肤银屑病(OR,1.70;95%CI,1.34-2.15)、炎症性肠病(OR,1.53;95%CI,1.14-2.03)、免疫介导性关节炎(OR,1.49;95%CI,1.20-1.85)和结缔组织疾病(OR,1.39;95%CI,1.00-1.93)。
本研究表明 IMD 会增加结节病的发病风险,并且会在有结节病的家族中聚集,表明 IMD 和结节病之间存在共同的病因。我们的发现需要进一步评估共同的遗传机制。